Patents Issued in October 18, 2018
-
Publication number: 20180298066Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.Type: ApplicationFiled: June 27, 2018Publication date: October 18, 2018Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
-
Publication number: 20180298067Abstract: The present invention relates to cosmetic compositions comprising polypeptides obtained or obtainable from Salmonidae hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for improving the cosmetic appearance of skin of a mammalian animal.Type: ApplicationFiled: June 18, 2018Publication date: October 18, 2018Applicant: AQUA BIO TECHNOLOGY ASAInventors: Bernt TH. Walther, Hans Kristian Leren, Fanny Fagot
-
Publication number: 20180298068Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.Type: ApplicationFiled: April 22, 2016Publication date: October 18, 2018Inventor: Steven M. ALBELDA
-
Publication number: 20180298069Abstract: Provided herein is a cell line with improved odorant receptor function comprising an activated endogenous RTP1 gene, which further expresses an RTP1 protein. Further provided herein is a method for specifically activating an endogenous RTP1 gene in a eukaryotic cell using a CRISPR/Cas9 derived technique. Also provided herein is a method for identifying compounds with desired effects such as perfume or aroma modulators in said cell line.Type: ApplicationFiled: June 9, 2016Publication date: October 18, 2018Applicant: Firmenich SAInventors: Hyo-Young JEONG, Patrick PFISTER, Matthew ROGERS
-
Publication number: 20180298070Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2 ??(I) wherein each symbol is as defined herein.Type: ApplicationFiled: March 30, 2018Publication date: October 18, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu, Mari Adachi, Shiro Takekawa, Tomoko Morimoto
-
Publication number: 20180298071Abstract: The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.Type: ApplicationFiled: May 11, 2018Publication date: October 18, 2018Applicant: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Christophe DE ROMEUF, Christophe Sirac
-
Publication number: 20180298072Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.Type: ApplicationFiled: June 27, 2018Publication date: October 18, 2018Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AGInventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stöcker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
-
Publication number: 20180298073Abstract: Modified FGF-21 polypeptides and uses thereof are provided.Type: ApplicationFiled: April 13, 2018Publication date: October 18, 2018Inventors: Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
-
Publication number: 20180298074Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.Type: ApplicationFiled: June 27, 2018Publication date: October 18, 2018Inventors: Jan TAVERNIER, Jennyfer BULTINCK, Frank PEELMAN, Gilles UZE
-
Publication number: 20180298075Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.Type: ApplicationFiled: April 11, 2018Publication date: October 18, 2018Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
-
Publication number: 20180298076Abstract: The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation.Type: ApplicationFiled: July 22, 2016Publication date: October 18, 2018Inventors: Elizabeth M. Murphy Topp, Hamed Tabatabaei Ghomi, Markus Lill, Shenbaga Moorthy Balakrishnan
-
Publication number: 20180298077Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.Type: ApplicationFiled: April 11, 2018Publication date: October 18, 2018Inventors: Rasmus JUST, Kirsten Lindegaard BOVBJERG, Ditte RIBER, Wayne Shaun RUSSELL
-
Publication number: 20180298078Abstract: The present invention relates to a method for preparing a fusion protein having an IgG Fc domain and, specifically, to a method for preparing a fusion protein having an IgG Fc domain, the method additionally comprising a step of culturing cells, which produce the fusion protein, at a decreased culture temperature, thereby increasing cell growth and cell viability so as to increase fusion protein productivity and inhibiting aggregate generation so as to improve quality and production yield.Type: ApplicationFiled: October 14, 2016Publication date: October 18, 2018Applicant: ALTEOGEN, INC.Inventors: Soon Jae PARK, Hye Shin CHUNG, Sun Ah YOU, Jeong Soo CHO
-
Publication number: 20180298079Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.Type: ApplicationFiled: April 5, 2018Publication date: October 18, 2018Inventors: Leo Lefrancois, Thomas A. Stoklasek
-
Publication number: 20180298080Abstract: The present invention relates to processes of obtaining Apo A-I from an Apo A-I containing protein fraction (A), comprising suspending the Apo A-I containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-I proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-I precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-I, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: ApplicationFiled: January 12, 2018Publication date: October 18, 2018Applicant: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20180298081Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.Type: ApplicationFiled: April 12, 2018Publication date: October 18, 2018Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Yee-Peng CHAN, Christopher C. BRODER
-
Publication number: 20180298082Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.Type: ApplicationFiled: March 29, 2018Publication date: October 18, 2018Inventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
-
Publication number: 20180298083Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: March 18, 2016Publication date: October 18, 2018Applicant: The United States of America, as repsented By the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20180298084Abstract: A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-II antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.Type: ApplicationFiled: October 14, 2016Publication date: October 18, 2018Applicant: ARSANIS BIOSCIENCES GMBHInventors: Eszter NAGY, Gábor NAGY, Valeria SZIJÁRTO, Luis Miguel GUACHALLA, Irina MIRKINA, Zehra VISRAM
-
Publication number: 20180298085Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: December 13, 2017Publication date: October 18, 2018Inventors: Henry Bernard Lowman, Shouchun Liu
-
Publication number: 20180298086Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.Type: ApplicationFiled: January 26, 2018Publication date: October 18, 2018Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Michael SIERKS, Huilai TIAN
-
Publication number: 20180298087Abstract: A humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell comprises a heavy chain and a light chain. The antibody binds a carboxymethyllysine-modified protein or peptide. A composition comprises a humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 13, 2018Publication date: October 18, 2018Inventor: Lewis S. Gruber
-
Publication number: 20180298088Abstract: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.Type: ApplicationFiled: June 19, 2018Publication date: October 18, 2018Inventors: Lawrence G. Lum, Randall J. Lee
-
Publication number: 20180298089Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: ApplicationFiled: June 27, 2018Publication date: October 18, 2018Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20180298090Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.Type: ApplicationFiled: June 27, 2017Publication date: October 18, 2018Inventors: Menotti Ruvo, Annamaria Sandomenico, Antonio Leonardi, Luca Sanguigno, Mary J.C. Hendrix, Elisabeth A. Seftor, Richard E.B. Seftor, Luigi Strizzi, Zhila Khalkhali-Ellis
-
Publication number: 20180298091Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.Type: ApplicationFiled: March 5, 2018Publication date: October 18, 2018Inventors: Jörg WISCHHUSEN, Markus JUNKER, Tina SCHÄFER, Dirk PÜHRINGER
-
Publication number: 20180298092Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.Type: ApplicationFiled: June 26, 2018Publication date: October 18, 2018Applicant: Novartis AGInventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
-
Publication number: 20180298093Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.Type: ApplicationFiled: March 5, 2018Publication date: October 18, 2018Inventors: Boris Labkovsky, Tariq Ghayur, Georgeen Gaza-Bulseco, Pratibha Mishra, Subramanya Hegde, Sudha Krishnan
-
Publication number: 20180298094Abstract: A method for diagnosis or aiding in the diagnosis of Sjögren's Syndrome (SS). The diagnosis method requires testing a sample obtained or derived from a subject for an amount of Taxilin alpha, wherein determining an amount of Taxilin alpha that is more than a reference comprises a diagnosis or aids in a diagnosis that the individual has SS, and wherein determining an amount of Taxilin alpha that is the same as or less than a reference indicates the individual does not have SS. A mAb or Taxilin alpha-binding fragment thereof (“Taxilin alpha”) having an antibody heavy chain; an antibody light chain, an antibody comprising a heavy chain and/or an antibody. A kit of the same monoclonal antibody or Taxilin alpha-binding fragment thereof. A method of making the Taxilin alpha. The making method requires separating the Taxilin alpha from a cell culture that expresses the Taxilin alpha.Type: ApplicationFiled: April 13, 2018Publication date: October 18, 2018Inventors: Long SHEN, Lakshmanan SURESH
-
Publication number: 20180298095Abstract: Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between CEACAM family members and TIM family members.Type: ApplicationFiled: April 24, 2015Publication date: October 18, 2018Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Yasuyuki KONDO, Amit GANDHI
-
Publication number: 20180298096Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.Type: ApplicationFiled: April 5, 2018Publication date: October 18, 2018Applicants: Merck Sharp & Dohme Corp., Agenus Inc.Inventors: Barbara Joyce-Shaikh, Luis A. Zuniga, Milan Blanusa, Andrea Claudia Schuster, Kornelia Schultze
-
Publication number: 20180298097Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: June 25, 2018Publication date: October 18, 2018Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F,. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
-
Publication number: 20180298098Abstract: The present invention relates to polypeptides comprising conditionally active chimeric antigen receptor (CAR) and a split-protein binding system, a VAR2CSA polypeptide, or any other targeting agent. The present invention further relates to poly-peptides comprising VAR2CSA polypeptides or other targeting agent, and a split-protein binding system.Type: ApplicationFiled: February 26, 2016Publication date: October 18, 2018Applicant: VAR2 Pharmaceutical ApSInventor: Mai-Britt Zocca
-
Publication number: 20180298099Abstract: The present invention provides methods and compositions for treating immune mediated adverse drug reactions using anti-?? TCR antibodies and fragments thereof. The adverse drug reactions treated according to the invention include severe cutaneous adverse reactions, idiosyncratic liver injury, and idiopathic drug-induced liver disease. The invention also provides methods and compositions for treating conditions such as epidermolysis bullosa, pemphigus vulgaris, cutaneous T cell lymphoma, and Goodpasture syndrome where T cells play a significant role. Anti-? TCR antibodies used in the treatment methods of the invention include T10B9, MEDI-500 and TOL101.Type: ApplicationFiled: September 16, 2016Publication date: October 18, 2018Inventor: Harry C. Ledebur, JR.
-
Publication number: 20180298100Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.Type: ApplicationFiled: June 9, 2016Publication date: October 18, 2018Applicant: MacroGenics, Inc.Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
-
Publication number: 20180298101Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.Type: ApplicationFiled: December 16, 2016Publication date: October 18, 2018Inventors: Nicholas D. Huntington, Sandra E. Nicholson, Jeff Babon, Tatiana Kolesnik
-
Publication number: 20180298102Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the 2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.Type: ApplicationFiled: May 17, 2016Publication date: October 18, 2018Inventors: Anton Wyss-Coray, Saul A. Villeda, Karoly Nikolich
-
Publication number: 20180298103Abstract: Phycoerythrin (PE) and peptide:MHCII (p:MHCII) reactive monoclonal antibodies; methods to generate monoclonal antibodies including, for example, peptide:MHC (p:MHC) reactive monoclonal antibodies; compositions including monoclonal antibodies; and uses thereof.Type: ApplicationFiled: April 13, 2018Publication date: October 18, 2018Inventors: Brian T. Fife, Justin A. Spanier, Marc K. Jenkins, Justin J. Taylor
-
Publication number: 20180298104Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Th17-mediated diseases. In particular, the present invention relates to a method of treating a Th17-mediated disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a CD95 antagonist.Type: ApplicationFiled: April 21, 2016Publication date: October 18, 2018Inventors: Patrick LEGEMBRE, Patrick BLANCO, Robin FLYNN
-
Publication number: 20180298105Abstract: Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.Type: ApplicationFiled: February 27, 2018Publication date: October 18, 2018Inventors: Mette D. Andersen, Jeff Dantzler, Richard J. Armitage, Rutillio Clark
-
Publication number: 20180298106Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: March 1, 2018Publication date: October 18, 2018Inventors: Michel DE WEERS, Tim WALSETH, Jan VAN DE WINKEL, Tom VINK, Paul PARREN
-
Publication number: 20180298107Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.Type: ApplicationFiled: May 14, 2018Publication date: October 18, 2018Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
-
Publication number: 20180298108Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: June 25, 2018Publication date: October 18, 2018Applicant: PFIZER INC.Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
-
Publication number: 20180298109Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: January 29, 2018Publication date: October 18, 2018Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Publication number: 20180298110Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in preventing hereditary angioedema attack or reducing the rate of hereditary angioedema attack.Type: ApplicationFiled: March 30, 2016Publication date: October 18, 2018Applicant: Dyax Corp.Inventors: Yung Chyung, Burt Adelman, Daniel J. Sexton
-
Publication number: 20180298111Abstract: Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds LPA. The antibody may be a humanized monoclonal antibody.Type: ApplicationFiled: March 13, 2018Publication date: October 18, 2018Inventors: Roger A. SABBADINI, Rosalia MATTEO
-
Publication number: 20180298112Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: April 9, 2018Publication date: October 18, 2018Inventors: Allan BRADLEY, E-Chiang LEE, Wei WANG, Dominik SPENSBERGER, Hui LIU, Jasper CLUBE, Qi LIANG
-
Publication number: 20180298113Abstract: Some variations provide a new nanolignocellulose composition comprising, on a bone-dry, ash-free, and acetyl-free basis, from 35 wt % to 80 wt % cellulose nanofibrils, cellulose microfibrils, or a combination thereof, from 15 wt % to 45 wt % lignin, and from 5 wt % to 20 wt % hemicelluloses. The hemicelluloses may contain xylan or mannan as the major component. Novel properties arise from the hemicellulose content that is intermediate between high hemicellulose content of raw biomass and low hemicellulose content of conventional nanocellulose. The nanolignocellulose composition is hydrophobic due to the presence of lignin. Processes for making and using the nanolignocellulose compositions are also described.Type: ApplicationFiled: June 21, 2018Publication date: October 18, 2018Inventors: Kimberly NELSON, Theodora RETSINA
-
Publication number: 20180298114Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd 21 1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.Type: ApplicationFiled: November 22, 2017Publication date: October 18, 2018Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Publication number: 20180298115Abstract: The invention relates to a complex of pure anthocyanidin and a sulfoalkyl ether ?-cyclodextrin, which complex can be formulated as an aqueous solution and as a solid, and a method for producing such a complex. Complexes according to the invention are storage-stable and can be well formulated as an aqueous solution.Type: ApplicationFiled: June 20, 2018Publication date: October 18, 2018Inventors: Norbert Roewer, Jens Broscheit
